It has been another busy week for many of Australia's top brokers. This has led to the release of a number of broker notes.
Three broker buy ratings that you might want to know more about are summarised below. Here's why brokers think these ASX shares are in the buy zone right now:
Image source: Getty Images
Domino's Pizza Enterprises Ltd (ASX: DMP)
According to a note out of Morgans, its analysts have retained their buy rating on this pizza chain operator's shares with a trimmed price target of $18.00. While Domino's delivered a result in line with expectations in FY 2025, it was disappointed with its trading update for FY 2026. However, it was not all bad news. It highlights that management is working fast to take significant costs out of the business, the European operations are improving, and an inflection point appears to be approaching. Overall, the broker still sees long-term value on offer with its shares but acknowledges that patience will be required. The Domino's share price is trading at $15.11 on Friday.
DroneShield Ltd (ASX: DRO)
A note out of Bell Potter reveals that its analysts have retained their buy rating on this counter drone technology company's shares with a slightly reduced price target of $3.70. The broker highlights that the company's performance in the first half of FY 2025 demonstrates the significant growth that has occurred in the business this year. This includes the acceleration of both the scale and frequency of contracts. And while it was disappointed that DroneShield didn't win the Land156 contract, it points out that this is just a very small slice of a huge sales pipeline that currently stands at $2.3 billion. The majority of which (95%>) is from overseas. The DroneShield share price is fetching $3.27 at the time of writing.
Telix Pharmaceuticals Ltd (ASX: TLX)
Analysts at Bell Potter have also retained their buy rating on this radiopharmaceuticals company's shares with a reduced price target of $23.00. According to the note, the broker was disappointed to see that the US FDA has not approved its Zircaix product. Instead, it has issued a Complete Response Letter (CRL) which summarised the reason for denial. Bell Potter highlights that this is the second CRL for Telix this calendar year. And the delay to revenues and the knock-on effect to the cost of capital and valuation are material. However, it believes the selloff has created an attractive entry point for investors and is recommending that they buy the dip. The Telix share price is trading at $14.63 this afternoon.
